<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nielsen, Jens Cosedis</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">MANTRA-PAF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-11-09 11:22:16</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">At 5 years, patients in the MANTRA-PAF trial treated with radiofrequency ablation had less atrial fibrillation burden and episodes of symptomatic atrial fibrillation compared with antiarrhythmic drug. However, there was no significant difference in quality of life measures.</style></abstract><number><style face="normal" font="default" size="100%">28 suppl 2</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>